Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2024)
Historic Cash & Equivalents for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $64.4 million.
- Solid Biosciences' Cash & Equivalents rose 3131.72% to $64.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $64.4 million, marking a year-over-year increase of 3131.72%. This contributed to the annual value of $74.0 million for FY2023, which is 5236.64% down from last year.
- As of Q3 2024, Solid Biosciences' Cash & Equivalents stood at $64.4 million, which was up 3131.72% from $95.9 million recorded in Q2 2024.
- Solid Biosciences' 5-year Cash & Equivalents high stood at $268.5 million for Q1 2021, and its period low was $24.8 million during Q3 2020.
- In the last 5 years, Solid Biosciences' Cash & Equivalents had a median value of $95.9 million in 2024 and averaged $106.1 million.
- In the last 5 years, Solid Biosciences' Cash & Equivalents plummeted by 7382.07% in 2020 and then surged by 40481.7% in 2021.
- Over the past 5 years, Solid Biosciences' Cash & Equivalents (Quarter) stood at $154.7 million in 2020, then decreased by 23.01% to $119.1 million in 2021, then soared by 30.43% to $155.4 million in 2022, then plummeted by 52.37% to $74.0 million in 2023, then decreased by 13.0% to $64.4 million in 2024.
- Its Cash & Equivalents stands at $64.4 million for Q3 2024, versus $95.9 million for Q2 2024 and $117.6 million for Q1 2024.